跳至主要内容
临床试验/NCT01824368
NCT01824368已完成1 期

FOTOAFERESIS EXTRACORPÓREA EN EL TRASPLANTE HEPÁTICO. ENSAYO CLINICO EN FASE II DE SEGURIDAD Y EFICACIA EN PACIENTES CON RETIRADA PROGRESIVA DE LA INMUNOSUPRESIÓN

Red de Terapia Celular2 个研究点 分布在 1 个国家目标入组 10 人开始时间: 2013年4月最近更新:
适应症

试验速览

阶段
1 期
状态
已完成
入组人数
10
试验地点
2
主要终点
adverse event rate and rate of transplant rejection

研究概览

简要总结

The purpose of this study is to evaluate the safety of extracorporeal photopheresis in patients with long-standing liver transplantation subjected to a progressive reduction of immunosuppression by complications arising from its use.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Have been receiving liver transplant two years ago.
  • Be 18 years or older.
  • Treatment with immunosuppression including cyclosporine or tacrolimus.
  • Having a normal liver function in the last year
  • Not have suffered acute rejection in the last year and have no chronic rejection
  • Submit any significant side effects from medication immunosuppressive (hypertension, creatinine greater than 1.7 mgDl, diabetes, morbid obesity, osteoporosis, hyperlipidemia, severe hirsutism, neurotoxicity novo malignancy, etc.)
  • Etiology of underlying disease: alcoholic cirrhosis with or without hepatocarcinoma, metabolic diseases, amyloidotic polyneuropathy family, biliary atresia, fulminant hepatitis non-A, non-B, non-C, cirrhosis cryptogenic and generally causes no viral or autoimmune.
  • Patients offering sufficient guarantees of adherence to protocol
  • Patients who give written informed consent for participate in the study.
  • It is necessary that the patient meets all inclusion criteria.

排除标准

  • Underlying disease of the autoimmune (primary sclerosing cholangitis, autoimmune cirrhosis, primary biliary cirrhosis) or epatocarcinoma about cirrhosis of viral or autoimmune.
  • Patients with chronic rejection, or acute rejection in the last year.
  • Patients with liver retransplantation.
  • patients with history of hypersensitivity or idiosyncratic reactions to methoxsalen, psoralen the compounds or any of the excipients.
  • patients with melanoma, cutaneous basal cell carcinoma or squamous cell coexistent.
  • Patients with aphakia.
  • Patients taking Oxoralen.
  • Pregnant women or nursing mothers, or adults of childbearing age not using effective contraception.
  • Participation in another clinical trial.
  • Inability to understand informed consent.

结局指标

主要结局

adverse event rate and rate of transplant rejection

时间窗: 1 year

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验